Organization
Amyotrophic Lateral Sclerosis Society of Canada
- Meetings this Parliament
- 74
- With MPs
- 47
- Since Nov 2021
- 94
- Active registrations
- 1
Most recent reported meeting: Oct 28, 2026.
Lobbying by Amyotrophic Lateral Sclerosis Society of Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (organization) In effect since Jan 12, 2026 Receives government funding
Filed by Tammy Moore, Chief Executive Officer
Lobbyists
- David Taylor · Chief Scientific Officer
- Ilayda Ulgenalp · Senior Manager, Advocacy and Stakeholder Relations
- Lauren Gallacher · Coordinator, Advocacy and Stakeholder Relations
- Tammy Moore · Chief Executive Officer
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), National Defence (DND), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (3)Hide details
- To provide funding for the Canadian Collaboration to Cure ALS, to establish a coordinated national research ecosystem through which every Canadian living with ALS can participate in, and benefit from, cutting-edge science that will accelerate discoveries by Canadian researchers, advance understanding of the disease, and enable the development of therapies to treat this devastating terminal illness with greater precision. Sources of funding are to be determined.
- Policies or programs related to access to care and potential treatments for the ALS Community.
- Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit.
Registration 895134-16791-38. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Tammy Moore · In-house (organization)
- Marie-France Lalonde · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Kerry Diotte · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Anita Vandenbeld · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Michael D. Chong · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Peter Fragiskatos · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Ben Carr · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- David Wells · Senator, Senate of Canada
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Supriya Sharma · Chief Medical Advisor, Health Canada (HC)
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Zoe Royer · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Doug Shipley · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Adam Chambers · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Maggie Chi · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Tamara Jansen · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Rodrigo Arancibia · Sr. Director for Innovation, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Tom Kmiec · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Fraser Tolmie · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Minister of Health's Office, House of Commons
- Bryn Savage · Policy Advisor, Minister of Health's Office, House of Commons
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Patricia Conrod · Scientific Director of the CIHR Institute of Neurosciences, Mental Health and Addiction, Canadian Institutes of Health Research (CIHR)
- Jane Rylett · Scientific Director of the CIHR Institute of Aging, Canadian Institutes of Health Research (CIHR)
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Marjorie Michel · Minister of Health
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Leslie Church · Member of Parliament
Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Bryn Savage · Policy advisor, Minister of Health's office, House of Commons
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
-
Reported by Tammy Moore · In-house (organization)
- Fares Al Soud · Member of Parliament
Policies or programs related to access to care and potential treatments for the ALS Community. Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
-
Reported by Tammy Moore · In-house (organization)
- Kiren Dar · Constituency Assistant, House of Commons
- Shelley Kulperger · Office Manager, House of Commons
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
-
Reported by Tammy Moore · In-house (organization)
- Peter Fragiskatos · Member of Parliament
- Marie-Hélène Gaudreau · Member of Parliament
- Judy A. Sgro · Member of Parliament
- Annie Koutrakis · Member of Parliament
and 2 moreShow fewer
- Zoe Royer · Member of Parliament
- Maggie Chi · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
-
Reported by Tammy Moore · In-house (organization)
- Peter Fragiskatos · Member of Parliament
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined. Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.